글로벌 재조합 기술 시장 – 2029년까지의 산업 동향 및 예측

재조합 기술 시장 분석 및 규모

재조합 기술은 많은 질병을 치료하는 데 빠르게 사용되고 있으며, 특히 새로운 의약품과 백신을 만드는 데 사용되고 있습니다. 이는 진단 도구, 모니터링 시스템, 새로운 치료 방법 등의 개발로 인한 치료 방법의 발전과 함께 시장의 주요 원동력 중 하나입니다. 또한 재조합 기술 시장은 생물학적 분해자이자 청정 연료 생산자로 여겨지는 미생물을 포함하는 유전자 변형 생물체(GMO)에 대한 연구 증가에 의해 주도되고 있습니다.

Data Bridge Market Research는 2021년에 6,904억 달러였던 재조합 기술 시장이 2029년까지 1조 1,272억 5,000만 달러로 급증할 것으로 분석했으며, 2022년부터 2029년까지의 예측 기간 동안 6.32%의 CAGR을 기록할 것으로 예상합니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

재조합 기술 시장 범위 및 세분화      

Market Definition

Recombinant technology is also known as genetic engineering. It is currently utilized frequently to modify genetic material outside of an organism to produce better and desirable features in living things. It involves inserting DNA fragments from various sources that have the desired gene sequence into a suitable vector. In addition, it helps in the safe, economical, and sufficient manufacturing of essential proteins needed for nutrition and battling health issues. As a result, it has applications across various fields and a great potential to enhance food resources, improve health, and increase resilience to various negative environmental effects.

Recombinant Technology Market Dynamics

Drivers

• Increasing biopharmaceutical industry

The recombinant technology market is expected to grow at a faster rate during the forecast period 2022 and 2029 due to factors including the expanding biopharmaceutical industry, an increase in technological advancement in the area, a rise in the awareness of human and animal health, and an increase in the success rate of recombinant insulin. On the other hand, government funding for recombinant technology in gene therapy, clinical diagnosis, and pharmaceutical production will create a wealth of growth prospects for the recombinant technology market during the forecast period.

• Increase in prevalence of infectious diseases

The rise in high-tech goods, the expansion of regulatory approvals, the high prevalence of infectious diseases, and the increased market penetration of major companies all contribute to the increased need for recombinant vaccines globally. The market is expanding due to improving healthcare awareness, attractive reimbursement policies, drug and vaccine research and development innovation, rising average individual incomes, and more.

Opportunities

Ongoing research studies fuel the market's growth to explore the potential of plant as expression system are expected to drive the adoption of plan expression systems for GM product development in the coming years. This will provide beneficial opportunities for market growth.

Moreover, an increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the recombinant technology market growth during the forecast period.

Restraints/Challenges

On the other hand, the scientific, regulatory and ethical challenges along with rising risk in using the genetically modified food will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the recombinant technology market.

• High vaccine costs and side effects of treatment

Market growth is likely to be impeded by factors such as high vaccine costs, risks associated with live attenuated vaccines, as well as sore throat irritability after vaccine administration, and strict regulatory policies. 

This recombinant technology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the recombinant technology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Recombinant Technology Market

The global pandemic COVID-19 has caused stress across many businesses and industry verticals, not just for human lives. Several million people around the world have contracted the COVID-19 disease, and with more cases becoming active every day, it is still difficult to forecast how long the pandemic will last. The COVID-19 outbreak has had a significant impact on recombinant technology. However, because vaccines are so effective at preventing fatal illnesses, their business has been expanding globally. The prognosis for the year predicts that increased R&D will result in the potential development of a COVID-19 recombinant vaccine.

Recent Development

• In February 2022, the European Medicines Agency's Committee for the Use of Medicinal Products provided VBI Vaccines Inc. with favorable feedback. This viewpoint was in reference to the PreHevbri 3-antigen hepatitis B (HBV) vaccine, developed to provide adults with immunity against hepatitis B virus infection. Because hepatitis B is still a concern for public health in Europe, this favourable judgment gave medical professionals a useful tool for preventing patients from contracting the illness.
• In June 2021, the world's top provider of life science research tools and services, GenScript USA Inc., debuted the GenWandTM Double-Stranded DNA (dsDNA) Service for manufacturing CRISPR knock-in homology-directed repair (HDR) templates in T cell engineering.
• In March 2022, PreHevbrio (Recombinant Hepatitis B Vaccine) was made available to individuals over the age of 18 in the United States by VBI Vaccines Inc. to prevent infection by any known subtype of the hepatitis B virus (HBV). Additionally, the release of the vaccine will increase immunization rates with the help of US healthcare experts and will protect patients, especially adult patients, against HBV.

Global Recombinant Technology Market Scope

The recombinant technology market is segmented on the basis of product, component, application and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Medical
• Therapeutic Agent
• Human Protein
• Vaccines
• Non-Medical
• Biotech Crops
• Specialty Chemicals
• Others

 Component

• Expression System
• Cloning Vector

Application

• Food and Agriculture
• Health and Disease
• Environment
• Others

 End Use

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Diagnostic Laboratories

Recombinant Technology Market Regional Analysis/Insights

The recombinant technology market is analysed and market size insights and trends are provided by country, product, component, application and end use as referenced above.

The countries covered in the recombinant technology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the recombinant technology market due to the prevalence of various biopharmaceutical companies along with the high adoption of advanced technology.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the prevalence of low-cost manufacturing centres.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

의료 인프라 성장 설치 기반 및 신기술 침투

재조합 기술 시장은 또한 자본 장비에 대한 의료 지출의 모든 국가별 성장, 재조합 기술 시장을 위한 다양한 종류의 제품의 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 글로벌 재조합 기술 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2010-2020년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 재조합 기술 시장 점유율 분석

재조합 기술 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 재조합 기술 시장과 관련된 회사의 초점에만 관련이 있습니다.

재조합 기술 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 암젠 주식회사(미국)
• 노바티스 AG(독일)
• Novo Nordisk A/S(덴마크)
• 사노피(프랑스)
• 머크앤코(미국)
• 제넨텍 주식회사(미국)
• 젠스크립트(미국)
• 파이저 주식회사(미국)
• Biocon(인도)
• GlaxoSmithKline plc. (영국)
• New England Biolabs (UK) Ltd. (영국)
• 시버스(미국)
• 호라이즌 디스커버리 유한회사(영국)
• 베링거인겔하임인터내셔널(독일)
• Thermo Fisher Scientific Inc. (미국)

SKU-54478